Login to Your Account



GW Pharma's Sativex Performs Well in MS Spasticity Study

By Nuala Moran
Staff Writer

Tuesday, August 13, 2013
LONDON – GW Pharma plc delivered positive results in a UK Phase III postmarketing study of Sativex, which will provide ballast for the launch of the cannabis-based product as a treatment for spasticity caused by multiple sclerosis in national markets across Europe and the Middle East.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription